Cargando…
A Case of COVID-19–Induced Lymphocytosis in a Patient With Treatment-Naive CLL: Should It Be treated?
Autores principales: | Safarpour, Damoun, Srinivasan, Krishnan, Farooqui, Marwah, Roth, Connor, Ghouse, Masood |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7499147/ https://www.ncbi.nlm.nih.gov/pubmed/33039356 http://dx.doi.org/10.1016/j.clml.2020.09.005 |
Ejemplares similares
-
Optimal Anticoagulant Dosing in Patients with COVID-19, a Retrospective Review
por: Carrillo, Alessandra, et al.
Publicado: (2021) -
The CLL International Prognostic Index predicts outcomes in monoclonal B-cell lymphocytosis and Rai 0 CLL
por: Parikh, Sameer A., et al.
Publicado: (2021) -
HLA specificities are associated with prognosis in IGHV-mutated CLL-like high-count monoclonal B cell lymphocytosis
por: García-Álvarez, María, et al.
Publicado: (2017) -
Immnuophenotypic and Gene Expression Analysis of Monoclonal B Cell Lymphocytosis Shows Biologic Characteristics Associated With Good Prognosis CLL
por: Lanasa, Mark C., et al.
Publicado: (2011) -
Polygenic risk score and risk of monoclonal B-cell lymphocytosis in caucasians and risk of chronic lymphocytic leukemia (CLL) in African Americans
por: Kleinstern, Geffen, et al.
Publicado: (2021)